Immunoglobulin G Complexes from Post-infectious ME/CFS, including post-COVID ME/CFS Disrupt Cellular Energetics and Alter Inflammatory Marker Secretion

Authors: Liu, Zheng; Hollmann, Claudia; Kalanidhi, Sharada; Lamer, Stephanie; Schlosser, Andreas; Basens, Emils Edgars; Nikolayshvili, Georgy; Sokolovska, Liba; Riemekasten, Gabriela; Rust, Rebekka; Bellmann-Strobel, Judith; Paul, Friedemann; Naviaux, Robert K.; Nora-Krukle, Zaiga; Sotzny, Franziska; Scheibenbogen, Carmen; Prusty, Bhupesh K.

Brain, Behavior, & Immunity - Health, Feb 2026

View article | Discussion on S4ME

Cohorts in this study

Phenotype: ME/CFS, ME/CFS - Canadian Consensus Criteria (CCC) 2003, Post-exertional malaise (PEM)

ARG1, AZU1, CFHR5, CPN1, DNM1L, DSC1, EEA1, FCN2, FGG, FN1, GRN, HBA2, HSP90AB1, IGHV1-58, IGHV1-69-2, IGHV3-16, IGHV3-66, IGHV4OR15-8, IGKV3-7, IL1B, IL5, IMMT, ITPR3, KLKB1, LMNA, LTA, LYZ, MIGA1, MPO, PGLYRP2, PLD6, PPL, PSMD6, SERPINB3, SPEG, TF, TIMM23, TTR, VWF, ZNF185

Search for these genes

Notes

"IgG from ME/CFS and PCS-CFS patients decreased the protein levels of Drp1 [DNM1L], mitofilin [IMMT], Miga1, and PLD6"
TIMM23 from Fig 2E.
Significant cytokines from Fig. 5B.
"IgM against fibronectin was negatively associated with disease severity."
Significant genes in Figs. 6D, 6E, 7C